The antiplatelet effect of low-dose aspirin is dependent on the preferential inhibition of platelet cyclooxygenase (COX)-1 which translates into a virtually complete inhibition of thromboxane (TX) A2, i.e., a potent lipid mediator which acts as an amplifier of the response to primary platelet agonists, such as thrombin and collagen.